Digg icon reddit icon Stumbleupon icon
Print Email     Print Edition Stories

Tuesday, June 3, 2008

Immune Disease Institute and GlaxoSmithKline in $25M partnership

By Mass High Tech Staff


Immunoinflammation research has brought together pharmaceutical giant GlaxoSmithKline and Boston’s Immune Disease Institute.

The collaboration, a five-year effort worth $25 million, enables the institute and GlaxoSmithKline to draft joint grant proposals through the partnership’s alliance research grant program. The partnership will run through GlaxoSmithKline’s Immuno-Inflammation Centre of Excellence in Drug Discovery.

Under terms of the agreement, GlaxoSmithKline (NYSE:GSK) benefits by getting exclusive rights for IDI immunological developments, and IDI gains competitive strength from the pharmaceutical company in return.

The non-profit Immune Disease Institute, affiliated with Harvard Medical School, provides biomedical research associated with inflammation and immune defense.
 

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.

Digg icon reddit icon Stumbleupon icon
Contact Editor Latest News

Tech Pulse Poll

What's your level of interest in Pinterest?



View Results

Stay Informed
Check which newsletter you'd like to receive.
TechFlash (Daily)
BioFlash (Daily)
GreenFlash (Weekly)
Startup Report (Weekly)
Breaking news, MHT events, local announcements
RSS feeds
Your email:

Affiliate publications: ACBJ.com, Boston Business Journal, Bizjournals.com, Portfolio.com, Wired.com

Web Site Developed by Neptune Web, Inc.

Use of and/or registration on any portion of this site constitutes acceptance of our User Agreement and Privacy Policy. About our ads.